Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models.

Pediatric blood & cancer - 1 May 2005

Parikh Nehal S, Currier Mark A, Mahller Yonatan Y, Adams Lisa C, Di Pasquale Betsy, Collins Margaret H, Cripe Timothy P

Abstract excerpt

BACKGROUND: High-risk neuroblastoma (Nb) is incurable using current treatment regimens in the majority of patients. Oncolytic virotherapy is a novel approach being tested for several types of adult cancers. OBJECTIVES: To compare the susceptibility of Nb tumor models to oncolytic adenovirus and H...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviruses, Human
Share to Integrins
Share to Necrosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms, Experimental

Share to Neuroblastoma

Share to Receptors, Virus

Share to Simplexvirus

Share to Transplantation, Heterologous

Source

Identifiers

PMID: 15570577
DOI: 10.1002/pbc.20268

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-15570577-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models.PMID 15570577Read ↗

Viral oncolysis by herpes simplex virus and other viruses.Semantic proximity Read ↗

Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibilitySemantic proximity Read ↗

Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy.Semantic proximity Read ↗

A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses.Semantic proximity Read ↗

Vesicular Stomatitis Virus as an Oncolytic Agent against Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

A novel Gorilla-derived oncolytic Adenovirus with natural selective replication in cancer cellsSemantic proximity Read ↗

Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved TolerabilitySemantic proximity Read ↗

Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir.Semantic proximity Read ↗

Permissiveness of Human Cancer Cells to Oncolytic Bovine Herpesvirus 1 Is Mediated in Part by KRAS ActivitySemantic proximity Read ↗

Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma.Semantic proximity Read ↗

HDAC inhibitor valproic acid enhances tumor cell kill in adenovirus‐HSVtk mediated suicide gene therapy in HNSCC xenograft mouse modelSemantic proximity Read ↗

Delta-24 adenoviral therapy for glioblastoma: evolution from the bench to bedside and future considerationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.